speb/financial-data huggingface dataset:
Financial scorecard for CJMB (Industrials — Integrated Freight & Logistics, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 3.18
Market cap: 14397601 (USD: 14397601)
P/B ratio: 4.412317532679851
Debt to equity: 1.391
Current ratio: 2
Return on net tangible assets (%): -200.87031652363532
Buffett classification: The Gruesome
Rule of 40 score: -195.39934550741944
Altman Z-score: -1.6723951362597331 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -1.6593875604692756
Total shareholder yield (%): -1.6593875604692756 (Minimal or Negative)
Momentum (%): 1m 335.61643835616445, 3m 208.73786407766994, 6m 7.070707070707069, 12m -38.84615384615385, composite 43.28234422894618 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 0, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -23.6814852174417
Revenue deceleration: no
Accrual ratio: -0.26116132060884745
FCF conversion rate: 0.5334877734557492
Beneish M-score: -1.3315598136930218 (Strong Manipulation Signal)
ROE (%): -163.71712600049088
Net margin (%): -290.65446330176115
Asset turnover: 0.19260556415339034
Equity multiplier (leverage): 2.9244775143523785
ROE archetype: Low Return
Treasury beta 1y: -0.002072990975730319 (R-squared: 8.88697574032963e-06)
Insider 90-day net shares: 37000 (net value USD: 57936.00)
ROIC (%): -233.26742853920314 (pretax: -295.27522599899123)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 72.07792207792207, ROIC 88.96103896103897, revenue growth 1y 55.1948051948052, 6m momentum 26.623376623376622
Sector percentiles: P/E , 6m momentum 28.827444956477215
Industry median P/E: 1.6524312026398307; industry median ROIC: 5.860649403527186
Sector median P/E: 0.48479532163742683; sector median ROIC: 7.0952301251284755
WACC: 0.07748978436059388
Base cash flow: -8431310
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CLYM (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 12.84
Market cap: 735257216 (USD: 735257216)
P/B ratio: 2.6488280889354083
Debt to equity: 0.0032
Current ratio: 27.86
Return on net tangible assets (%): -9.240638822298004
Buffett classification: The Gruesome
Analyst consensus upside (%): 205.54744525547446
Rule of 40 score: 0
Altman Z-score: 100.64865259858212 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.008432423191614077
Total shareholder yield (%): 0.008432423191614077 (Low Return)
Momentum (%): 1m 0.7058823529411754, 3m 40.48140043763675, 6m 155.7768924302789, 12m 767.5675675675675, composite 319.2482597848007 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.004104762023766384
FCF conversion rate: 1.0478793178836905
Beneish M-score: -2.5502040333716214 (Likely Safe)
ROE (%): -8.894218304381644
Asset turnover: 0
Equity multiplier (leverage): 1.0374513870884108
ROE archetype: Low Return
Treasury beta 1y: -0.003228565319432717 (R-squared: 0.00020420117771179438)
Insider 90-day net shares: -30902 (net value USD: -406979.00)
ROIC (%): -89.4747230379071 (pretax: -113.25914308595834)
Incremental ROIC 3y (%): -33.0913510228884 (pretax: -41.88778610492202)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 30.505415162454874, ROIC 23.826714801444044, revenue growth 1y , 6m momentum 1.3537906137184115
Sector percentiles: P/E , 6m momentum 0.9670487106017192
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.051303654687485115
Base cash flow: -59940000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CMA.AX (Consumer Cyclical — Auto & Truck Dealerships, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.6944444444444444
Market cap: 137417248 (USD: 89815194.77124183)
Debt to equity: 0.3091
Current ratio: 4.17
Interest coverage ratio: -7.829268292682926
Return on net tangible assets (%): -38.20359281437125
Buffett classification: The Gruesome
Rule of 40 score: -29.075752216706725
Altman Z-score: 3.766513323327727 (Safe Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 32.49269005847952, 3m 20.02743484224964, 6m -51.01986044015029, 12m , composite -15.496212798950324 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue growth 1y (%): 1.5965166908562978
Revenue deceleration: yes
Revenue growth consistency score: 30.33636189166772
Accrual ratio: -0.2671755725190839
FCF conversion rate: 0.6100278551532035
Beneish M-score: -2.680200383515906 (Likely Safe)
ROE (%): -82.43398392652124
Net margin (%): -50.280112044817926
Asset turnover: 1.3625954198473282
Equity multiplier (leverage): 1.2032146957520093
ROE archetype: Low Return
Treasury beta 1y: 0.0029410676476286433 (R-squared: 0.0002757908207103225)
Insider 90-day net shares: 50329 (net value USD: 52181.00)
ROIC (%): -88.05208333333334 (pretax: -111.45833333333333)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC 89.47368421052632, revenue growth 1y 31.57894736842105, 6m momentum 78.94736842105263
Sector percentiles: P/E , 6m momentum 84.14464534075104
Industry median P/E: 6.095544247836901; industry median ROIC: 4.734603494045294
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.11067304971740163
Base cash flow: -20849673.202614374
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CMET.L (Basic Materials — Other Industrial Metals & Mining, British Virgin Islands)
Report date: 2025-09-30 (quarterly)
Stock price: 0.0006666666666666666
Market cap: 23384222 (USD: 31600300)
P/B ratio: 0.018758386586308684
Debt to equity: 0
Current ratio: 7.66407768209488
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 1.3333333333333321, 3m -1.3333333333333421, 6m 23.33333333333333, 12m 64.44444444444444, composite 28.093567251461987 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.4774441660704247 (Likely Safe)
Equity multiplier (leverage): 1.162106621616979
ROE archetype: Standard Business
Treasury beta 1y: -0.0007960094243075688 (R-squared: 1.0396166070036959e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -16.558832961873986 (pretax: -20.96054805300505)
Incremental ROIC 3y (%): 39.30035582533523 (pretax: 49.747285854854724)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B 2.4146544546211492, ROIC 31.80682764363031, revenue growth 1y , 6m momentum 8.49292256452956
Sector percentiles: P/E , 6m momentum 9.55024986118823
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.1019
Base cash flow: -2326228.5714285714
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CNRI.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2025-12-31 (annual)
Stock price: 0.1347517730496454
Market cap: 22292462 (USD: 16271870.0729927)
P/B ratio: 1.4750674008169717
Debt to equity: 0
Current ratio: 0.2
Interest coverage ratio: -20.91969589457679
Return on net tangible assets (%): -1.6554533531168925
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 3.488422254340991 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0.3436946533765539
Debt paydown yield (%): 4.143394024677663
Total shareholder yield (%): 4.487088678054217 (Moderate Return)
Momentum (%): 1m 0.7092198581560165, 3m -38.46335697399527, 6m -64.91368928141308, 12m -73.81965552178319, composite -59.12702346675919 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.007167499715696904
FCF conversion rate: 1.4581438079638582
Beneish M-score: -2.5136609202634843 (Likely Safe)
ROE (%): -1.6916528570376874
Asset turnover: 0
Equity multiplier (leverage): 1.0812979594249355
ROE archetype: Low Return
Treasury beta 1y: 0.0020674451366608647 (R-squared: 8.344778615733261e-05)
Insider 90-day net shares: 51500 (net value USD: 6242.00)
ROIC (%): -1.9129259008184936 (pretax: -2.4214251909094853)
Incremental ROIC 3y (%): 10.525081735021777 (pretax: 13.322888272179464)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 21.89841798501249, ROIC 9.325562031640299, revenue growth 1y , 6m momentum 76.1865112406328
Sector percentiles: P/E , 6m momentum 80.1776790671849
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.05
Base cash flow: -515075.1824817518
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CNTA (Healthcare — Biotechnology, United Kingdom)
Report date: 2026-03-31 (quarterly)
Stock price: 40.5
Market cap: 6266618368 (USD: 6266618368)
P/B ratio: 9.584331875876785
Debt to equity: 0.2433
Current ratio: 9.53
Interest coverage ratio: -29.21017942145734
Return on net tangible assets (%): -16.21059284125512
Buffett classification: The Gruesome
Analyst consensus upside (%): 1.334340382678754
Rule of 40 score: 0
Altman Z-score: 15.918599328125298 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.06352554181408152
Total shareholder yield (%): 0.06352554181408152 (Low Return)
Momentum (%): 1m 1.8611670020120776, 3m 46.84554024655549, 6m 63.372327551432036, 12m 208.21917808219177, composite 104.26846227462089 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 9, recommendation: Short
Revenue growth 1y (%): -100
Revenue deceleration: no
Accrual ratio: -0.010412223242407205
FCF conversion rate: 0.9114473567976173
Beneish M-score: -2.5553060592218793 (Likely Safe)
ROE (%): -15.409783334520283
Asset turnover: 0
Equity multiplier (leverage): 1.310553004559207
ROE archetype: Low Return
Treasury beta 1y: -0.00034577377222153743 (R-squared: 5.224952679494904e-06)
Insider 90-day net shares: -10026863 (net value USD: -405409776.00)
ROIC (%): -46.79028357630096 (pretax: -59.228207058608795)
Incremental ROIC 3y (%): -4.700519085156484 (pretax: -5.950024158425931)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 57.03971119133574, ROIC 19.584837545126355, revenue growth 1y 29.693140794223826, 6m momentum 5.866425992779783
Sector percentiles: P/E , 6m momentum 4.369627507163324
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.10680537268354906
Base cash flow: -266191891.8918919
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CNVI.V (Healthcare — Medical Devices, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.12056737588652484
Market cap: 17076142 (USD: 12284994.244604317)
Debt to equity: -1.303492199799628
Current ratio: 1.4
Interest coverage ratio: -13.544378698224852
Buffett classification: The Gruesome
Rule of 40 score: -5538.917309342363
Altman Z-score: -17.50511868219451 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 3.927920172351395
Total shareholder yield (%): 3.927920172351395 (Low Return)
Momentum (%): 1m -28.6643026004728, 3m -59.712852447673406, 6m -63.02600472813239, 12m -67.84869976359337, composite -59.22281154686485 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 1, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 130.58794343835274
Revenue deceleration: no
Revenue growth consistency score: 161.1867318496245
Accrual ratio: 0.1670258873210832
FCF conversion rate: 1.4237677527151211
Beneish M-score: -1.0005061969761124 (Strong Manipulation Signal)
Net margin (%): -3683.0769230769233
Asset turnover: 0.010701510769709618
ROE archetype: Standard Business
Treasury beta 1y: 0.0009490891954742282 (R-squared: 2.9418973767886463e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y 2.3738872403560833, 6m momentum 72.10682492581603
Sector percentiles: P/E , 6m momentum 74.39111747851003
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.15
Base cash flow: -14227338.129496405
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for COBR.L (Basic Materials — Other Precious Metals & Mining, United Kingdom)
Report date: 2025-12-31 (annual)
Stock price: 0.0005333333333333334
Market cap: 43968964 (USD: 59417518.91891892)
P/E ratio: 3.017564759379395
P/B ratio: 0.06775037474298436
Debt to equity: 0
Current ratio: 7.26
Interest coverage ratio: -13797.184782608696
Return on net tangible assets (%): -7.07119105739053
Buffett classification: The Gruesome
Analyst consensus upside (%): 1820300
Rule of 40 score: 0
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 1.3333333333333406, 3m -21.066666666666666, 6m -1.3333333333333302, 12m 31.55555555555557, composite 2.474853801169593 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 7, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: 0.29588835861122587
FCF conversion rate: -9.897092095681225
Beneish M-score: 23.15409161391628 (Strong Manipulation Signal)
ROE (%): 2.8454346452472326
Asset turnover: 0
Equity multiplier (leverage): 1.0479277903001871
ROE archetype: Low Return
P/E z-score: 1.611172479252936
Treasury beta 1y: -0.0009604544829792189 (R-squared: 7.96610546200884e-06)
Insider 90-day net shares: 10562500 (net value USD: 559812.00)
ROIC (%): -21.97459595090508 (pretax: -21.97459595090508)
Incremental ROIC 3y (%): -26.644671347427213 (pretax: -24.01009946336257)
Capital allocation category: Value Destroyer
Industry percentiles: P/E 4.871060171919771, P/B 2.5787965616045847, ROIC 33.5243553008596, revenue growth 1y , 6m momentum 13.753581661891118
Sector percentiles: P/E 20.57190449750139, 6m momentum 25.402554136590783
Industry median P/E: 8.740359897172237; industry median ROIC: -12.638421644657798
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.07275000000000001
Base cash flow: -765614.8648648649
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for COYA (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 4.25
Market cap: 99693032 (USD: 99693032)
P/B ratio: 1.8872906186517722
Debt to equity: 0
Current ratio: 15.02
Return on net tangible assets (%): -14.711313129002932
Buffett classification: The Gruesome
Analyst consensus upside (%): 286.04060913705587
Rule of 40 score: -3327.713411085787
Altman Z-score: 12.741768344518952 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -20.11278195488722, 3m -1.620370370370377, 6m -9.957627118644064, 12m -36.75595238095238, composite -10.803776940782589 (Strong Downtrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue growth 1y (%): -2.6124148842115114
Revenue deceleration: no
Accrual ratio: -0.019345998827529316
FCF conversion rate: 0.8614594997356733
Beneish M-score: -2.2404175941185236 (Likely Safe)
ROE (%): -15.667609688365877
Net margin (%): -2869.630136931757
Asset turnover: 0.004866183490112278
Equity multiplier (leverage): 1.121988326125433
ROE archetype: Low Return
Treasury beta 1y: -0.004300183144142571 (R-squared: 0.0007934361103635636)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 22.292418772563177, ROIC , revenue growth 1y 19.043321299638986, 6m momentum 35.1985559566787
Sector percentiles: P/E , 6m momentum 40.114613180515754
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07495
Base cash flow: -21198746
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CPBI (Financial Services — Banks - Regional, United States)
Report date: 2026-03-31 (annual)
Stock price: 19.8
Market cap: 82818984 (USD: 82818984)
P/E ratio: 16.295238095238094
P/B ratio: 0.8042174903921788
Debt to equity: 0
Return on net tangible assets (%): 4.614168783516794
Buffett classification: The Gruesome
Rule of 40 score: 34.82260466295388
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0.8198603354032935
Total shareholder yield (%): 0.8198603354032935 (Low Return)
Momentum (%): 1m 4.761904761904773, 3m 13.924050632911403, 6m 17.437722419928832, 12m 32.00000000000001, composite 19.120591017613407 (Strong Uptrend)
Lynch category: Asset Play (confidence: Medium)
Screener: long score 4, short score 2, recommendation: Neutral
Revenue growth 1y (%): 11.864316806455033
Net income growth 1y (%): 9.469074986316372
Net income CAGR 3y (%): 34.44460725970442
FCF CAGR 3y (%): 11.668017499099935
Revenue deceleration: no
Revenue growth consistency score: 1.083866442002582
Accrual ratio: -0.0045760861122913785
FCF conversion rate: 3.6219895287958117
Beneish M-score: -2.4977840145294037 (Likely Safe)
ROE (%): 1.0806345757802067
Net margin (%): 17.99171062547099
Asset turnover: 0.009700425353052171
Equity multiplier (leverage): 6.191781519451422
ROE archetype: Low Return
P/E z-score: 4.0835524361273325
FCF z-score: 3.2011841113685886
Treasury beta 1y: 5.281709304057917e-07 (R-squared: 1.7609004059846805e-10)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 78.57142857142857, P/B 29.96894409937888, ROIC , revenue growth 1y 29.19254658385093, 6m momentum 37.88819875776397
Sector percentiles: P/E 44.46456285566477, 6m momentum 14.562855664769788
Industry median P/E: 10.091388400702987; industry median ROIC: 0.8427644093631484
Sector median P/E: 9.286368843069873; sector median ROIC: 1.3915857507207385
WACC: 0.05790000000000001
Base cash flow: 4087000
DCF price per share: base 73.81296423544231, conservative 43.6510139476141, aggressive 131.35154067919305
Financial scorecard for CRD.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.0425531914893617
Market cap: 6090796 (USD: 4381867.62589928)
P/E ratio: 3.237410071942446
P/B ratio: 2.6757072535134747
Debt to equity: 0
Current ratio: 21.02
Return on net tangible assets (%): -41.35010222589155
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 11.864460622226435 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 20.851063829787226, 3m -41.702127659574465, 6m -2.1276595744680846, 12m 92.90780141843973, composite 5.264875303832459 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.2078189306234525
FCF conversion rate: 0.4032489896987923
Beneish M-score: -2.3968647713139006 (Likely Safe)
ROE (%): -36.811728869300254
Asset turnover: 0
Equity multiplier (leverage): 1.0570469363780866
ROE archetype: Low Return
P/E z-score: 2.838122799487871
Treasury beta 1y: -0.028364108592969256 (R-squared: 0.0033625881029121776)
Insider 90-day net shares: 27778 (net value USD: 1277.00)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 6.577851790174854, P/B 33.38884263114071, ROIC , revenue growth 1y , 6m momentum 21.815154038301415
Sector percentiles: P/E 20.68295391449195, 6m momentum 26.790671848972792
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.15
Base cash flow: 1980783.211678832
DCF price per share: base 0.2576928891500474, conservative 0.20491190125077174, aggressive 0.32970231018502494
Financial scorecard for CRDL (Healthcare — Drug Manufacturers - Specialty & Generic, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 1.18
Market cap: 136021232 (USD: 136021232)
P/B ratio: 8.93714136809002
Debt to equity: 0.0048
Current ratio: 4.39
Return on net tangible assets (%): -44.78506137901415
Buffett classification: The Gruesome
Analyst consensus upside (%): 443.7037037037037
Rule of 40 score: 0
Altman Z-score: 5.670707722646684 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.0057901733659479005
Total shareholder yield (%): 0.0057901733659479005 (Low Return)
Momentum (%): 1m 14.563106796116495, 3m -15.714285714285714, 6m 13.461538461538453, 12m -15.714285714285714, composite -9.560439560439562 (Strong Downtrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.1175110455399879
FCF conversion rate: 0.6992793607373382
Beneish M-score: -2.774026761513929 (Likely Safe)
ROE (%): -51.10096849580476
Asset turnover: 0
Equity multiplier (leverage): 1.3077167207886227
ROE archetype: Low Return
Treasury beta 1y: -0.0026035320635327992 (R-squared: 0.00027914677573429307)
Insider 90-day net shares: 150000 (net value USD: 150000.00)
Incremental ROIC 3y (%): 150.867628952052 (pretax: 190.9716822177873)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 73.60703812316716, ROIC , revenue growth 1y , 6m momentum 24.04692082111437
Sector percentiles: P/E , 6m momentum 18.12320916905444
Industry median P/E: 0.8814835040505258; industry median ROIC: 5.747543732928968
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07493651219390458
Base cash flow: -24628740.875912406
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for CVB.AX (Healthcare — Medical Devices, United States)
Report date: 2025-06-30 (annual)
Stock price: 0.01388888888888889
Market cap: 8709231 (USD: 8709231)
Debt to equity: 0.4693
Current ratio: 2.88
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -32.87037037037037, 3m -67.5925925925926, 6m -74.65277777777779, 12m -73.78472222222221, composite -67.7312154108131 (Strong Downtrend)
Lynch category:  (confidence: Low)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Revenue growth consistency score: 14.569265707430718
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.000706313533539182 (R-squared: 5.490931200451937e-06)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 76.26112759643917
Sector percentiles: P/E , 6m momentum 77.43553008595988
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.15
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for DIAM.TO (Basic Materials — Other Precious Metals & Mining, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.014184397163120569
Market cap: 15478282 (USD: 11135454.676258994)
P/B ratio: 4.885821275252525
Debt to equity: 0.0059
Current ratio: 1.03
Interest coverage ratio: -54.57142857142857
Return on net tangible assets (%): -20.686026936026938
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: -98.90322349219633 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.18618034125605912
Total shareholder yield (%): 0.18618034125605912 (Low Return)
Momentum (%): 1m -32.86052009456264, 3m -51.41843971631205, 6m -51.06382978723405, 12m -61.41843971631206, composite -48.33916025705057 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: -0.050863712924689934
FCF conversion rate: 0.4284490145672665
Beneish M-score: -2.6962974371159194 (Likely Safe)
ROE (%): -22.824711316562084
Asset turnover: 0
Equity multiplier (leverage): 2.5647923627821254
ROE archetype: Low Return
Treasury beta 1y: -0.00036597563976925053 (R-squared: 6.376756001149011e-07)
Insider 90-day net shares: 133333333 (net value USD: 2933333.00)
ROIC (%): -61.80283477892956 (pretax: -78.23143642902475)
Incremental ROIC 3y (%): -11.08474027035785 (pretax: -14.031316797921335)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 39.541547277936964, ROIC 40.97421203438395, revenue growth 1y , 6m momentum 61.03151862464183
Sector percentiles: P/E , 6m momentum 72.68184342032204
Industry median P/E: 8.740359897172237; industry median ROIC: -12.638421644657798
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.113957374266394
Base cash flow: -2101459.8540145988
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for DML.TO (Energy — Uranium, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 2.9078014184397163
Market cap: 3710569472 (USD: 2669474440.28777)
P/B ratio: 17.151278629430312
Debt to equity: 2.8062
Current ratio: 13.77
Interest coverage ratio: -2.0927371223946376
Return on net tangible assets (%): -47.415622357192284
Buffett classification: The Gruesome
Analyst consensus upside (%): 88.62271805273834
Rule of 40 score: -4677.160179558132
Altman Z-score: 1.2441377693668965 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.13676929501858495
Total shareholder yield (%): -0.13676929501858495 (Minimal or Negative)
Momentum (%): 1m -8.446163765312702, 3m -23.390616475722855, 6m -24.854570085265763, 12m 27.98090385365742, composite -2.819197896615298 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 0, short score 13, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -17.248920863309348
Revenue deceleration: no
Accrual ratio: -0.058501315959637916
FCF conversion rate: 0.4325681804333255
Beneish M-score: -4.452517724516948 (Likely Safe)
ROE (%): -36.24585442560974
Net margin (%): -10386.889692585895
Asset turnover: 0.000992582079761905
Equity multiplier (leverage): 3.5156561508227364
ROE archetype: Low Return
Treasury beta 1y: -0.005443597207317152 (R-squared: 0.0015096339309320693)
Insider 90-day net shares: 0 (net value USD: -2676.00)
ROIC (%): -54.49657042462558 (pretax: -68.98300053750074)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 69.51219512195121, ROIC 57.3170731707317, revenue growth 1y 10.975609756097562, 6m momentum 21.951219512195124
Sector percentiles: P/E , 6m momentum 66.20416253716552
Industry median P/E: 18.936598557423494; industry median ROIC: -13.899740371778044
Sector median P/E: 11.598358576086895; sector median ROIC: 4.629877910100043
WACC: 0.1301408237535965
Base cash flow: -182449635.03649634
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for DT (Technology — Software - Application, United States)
Report date: 2026-03-31 (annual)
Stock price: 41.62
Market cap: 12131220480 (USD: 12131220480)
P/E ratio: 68.48148148148147
P/B ratio: 4.127599709863329
Debt to equity: 0.0629
Current ratio: 1.35
Return on net tangible assets (%): 12.48138553029838
Buffett classification: The Great
Analyst consensus upside (%): 28.745267712276917
Rule of 40 score: 30.20885116788191
Altman Z-score: 4.4887568017204575 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 7.287053860832884, earnings yield % 0.5022455867936414, rank 1387
Dividend yield (%): 0
Buyback yield (%): 1.8437963465321505
Debt paydown yield (%): -0.6471319199039073
Total shareholder yield (%): 1.1966644266282431 (Low Return)
Momentum (%): 1m 2.4870721497168136, 3m 17.937092660810425, 6m 2.0348124540328474, 12m -23.238657322021396, composite -1.709844489568411 (Strong Downtrend)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 7, short score 6, recommendation: Neutral
Revenue growth 1y (%): 18.820698152627656
Net income growth 1y (%): -66.3687448830228
Revenue CAGR 3y (%): 20.32772859547862
Net income CAGR 3y (%): 14.643291871120523
FCF CAGR 3y (%): 16.67720718211445
Revenue deceleration: no
Revenue growth consistency score: 2.711024016194002
Accrual ratio: -0.08575025630002467
FCF conversion rate: 3.2549717524543706
Beneish M-score: -2.5143143423383876 (Likely Safe)
ROE (%): 6.2175945974974285
Net margin (%): 8.059356307784386
Asset turnover: 0.47183914071610655
Equity multiplier (leverage): 1.6350388664162592
ROE archetype: Standard Business
P/E z-score: 4.21367964592746
FCF z-score: 4.213679645927459
Treasury beta 1y: 0.00908340704825663 (R-squared: 0.009647629472457422)
Insider 90-day net shares: -247 (net value USD: -10421.00)
ROIC (%): 10.697269228922439 (pretax: 16.457337275265292)
Incremental ROIC 3y (%): 20.50908502463877 (pretax: 35.72642612544893)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 52.02156334231805, P/B 49.46091644204852, ROIC 32.47978436657682, revenue growth 1y 20.485175202156334, 6m momentum 20.754716981132077
Sector percentiles: P/E 50.51718385051719, 6m momentum 29.796463129796464
Industry median P/E: 2.1394954536591486; industry median ROIC: 6.21806735836372
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.08646777486376106
Base cash flow: 154555000
DCF price per share: base 26.411281904501994, conservative 16.254919139539826, aggressive 44.8823690629445
Financial scorecard for EBM.V (Healthcare — Biotechnology, Canada)
Report date: 2026-04-30 (quarterly)
Stock price: 0.7021276595744681
Market cap: 68197112 (USD: 49778913.86861313)
Debt to equity: -0.03960413343602064
Current ratio: 0.05
Buffett classification: The Gruesome
Rule of 40 score: -4.591596831080279
Altman Z-score: -21.948409579868315 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.011424498119183961
Total shareholder yield (%): 0.011424498119183961 (Low Return)
Momentum (%): 1m 10.780141843971625, 3m 47.986906710310976, 6m 61.489361702127646, 12m 151.28779395296752, composite 78.77032025905108 (Strong Uptrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 4, short score 7, recommendation: Neutral
Revenue growth 1y (%): 90.19592297236632
Revenue deceleration: no
Revenue growth consistency score: 70.20651974623884
Accrual ratio: -0.26395463514710754
FCF conversion rate: -0.03404639951792709
Beneish M-score: -3.330832077586881 (Likely Safe)
Net margin (%): -45.78625722523417
Asset turnover: 0.5575118749177937
ROE archetype: Standard Business
FCF z-score: 2.008926222122276
Treasury beta 1y: 0.0008641289207948421 (R-squared: 6.722834802127428e-06)
Insider 90-day net shares: -127700 (net value USD: -86325.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y 6.137184115523466, 6m momentum 6.31768953068592
Sector percentiles: P/E , 6m momentum 4.656160458452722
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05349925091517072
Base cash flow: -205574.2857142857
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for EBR.AX (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 0.20833333333333334
Market cap: 225991696 (USD: 225991696)
P/E ratio: 2.6113013698630136
P/B ratio: 32.99824565472788
Debt to equity: 6.2418
Current ratio: 4.48
Interest coverage ratio: -12.288753799392097
Return on net tangible assets (%): -212.19333193541624
Buffett classification: The Gruesome
Analyst consensus upside (%): 1943.9999999999998
Rule of 40 score: -882.489552321071
Altman Z-score: -5.402791674539347 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.4185994515479896
Total shareholder yield (%): -0.4185994515479896 (Minimal or Negative)
Momentum (%): 1m -20.504385964912284, 3m -55.128205128205146, 6m -67.6418439716312, 12m -76.86887254901961, composite -64.55756200555736 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 0, short score 13, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.07286267970616071
FCF conversion rate: 1.378763031509898
Beneish M-score: -0.16186081575232364 (Strong Manipulation Signal)
ROE (%): -97.2157376302454
Net margin (%): -722.8619813717189
Asset turnover: 0.026612285366623103
Equity multiplier (leverage): 5.053578545806525
ROE archetype: Low Return
Treasury beta 1y: -0.009253416763185555 (R-squared: 0.00398751006272262)
Insider 90-day net shares: 575791 (net value USD: 153356.00)
ROIC (%): -117.4967889760222 (pretax: -148.73011262787622)
Incremental ROIC 3y (%): -52.73061021968128 (pretax: -66.74760787301429)
Capital allocation category: Value Destroyer
Industry percentiles: P/E 10.682492581602373, P/B 65.8753709198813, ROIC 58.753709198813056, revenue growth 1y , 6m momentum 74.4807121661721
Sector percentiles: P/E 15.866762177650429, 6m momentum 75.7163323782235
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07702945273097568
Base cash flow: -52038000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for EBS (Healthcare — Drug Manufacturers - Specialty & Generic, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 7.26
Market cap: 374589120 (USD: 374589120)
P/E ratio: 15.744457970588236
P/B ratio: 0.8186756964251577
Debt to equity: 1.1176000000000001
Current ratio: 4.29
Interest coverage ratio: 0.9545454545454546
Return on net tangible assets (%): 52.94117647058824
Buffett classification: The Great
Rule of 40 score: -21.34798108038051
Altman Z-score: 0.7036063468872698 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 1.5254976027894813, earnings yield % 1.3143251244408036, rank 1835
Dividend yield (%): 0
Buyback yield (%): 2.402632516395564
Debt paydown yield (%): -0.40043875273259405
Total shareholder yield (%): 2.0021937636629703 (Low Return)
Momentum (%): 1m -13.87900355871886, 3m -9.589041095890407, 6m -39.246861924686186, 12m -2.811244979919678, composite -11.99483246602888 (Moderate Uptrend)
Lynch category: Asset Play (confidence: Medium)
Screener: long score 2, short score 4, recommendation: Neutral
Revenue growth 1y (%): -28.407460545193686
Net income growth 1y (%): -90
Revenue deceleration: no
Accrual ratio: 0.0325881015536188
FCF conversion rate: -5.323529411764706
Beneish M-score: -1.9945214723406157 (Likely Safe)
ROE (%): 1.3005642153581334
Net margin (%): 4.542418169672679
Asset turnover: 0.11345206517620311
Equity multiplier (leverage): 2.523668356125084
ROE archetype: Low Return
P/E z-score: 1.290505537368245
FCF z-score: 2.5244874264560835
Treasury beta 1y: 0.005000126026197715 (R-squared: 0.0007139988358161637)
Insider 90-day net shares: -64925 (net value USD: -543440.00)
ROIC (%): 8.20814123467896 (pretax: 12.627909591813784)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 42.52199413489736, P/B 16.715542521994134, ROIC 34.31085043988269, revenue growth 1y 67.15542521994135, 6m momentum 79.17888563049853
Sector percentiles: P/E 21.669054441260744, 6m momentum 65.0429799426934
Industry median P/E: 0.8814835040505258; industry median ROIC: 5.747543732928968
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.12442276946785541
Base cash flow: 124000000
DCF price per share: base 16.859088674638585, conservative 14.879678747700426, aggressive 19.108732965506157
Financial scorecard for EIKN (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 8.9
Market cap: 481833760 (USD: 481833760)
P/B ratio: 1.040161338149276
Debt to equity: 0.4628
Current ratio: 11.75
Return on net tangible assets (%): -14.183968285963852
Buffett classification: The Gruesome
Analyst consensus upside (%): 134.40453686200377
Rule of 40 score: 0
Altman Z-score: -0.34349152680323813 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.5163606634786239
Total shareholder yield (%): 0.5163606634786239 (Low Return)
Momentum (%): 1m -7.580477673935622, 3m -7.8674948240165605, 6m , 12m , composite -7.8674948240165605 ()
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.00983010044550209
FCF conversion rate: 1.0856457484510234
Beneish M-score: -0.41452396323566026 (Strong Manipulation Signal)
Asset turnover: 0
ROE archetype: Standard Business
Treasury beta 1y: 0.0017620194284069463 (R-squared: 0.0001535524527129707)
Insider 90-day net shares: 2839978 (net value USD: 43707444.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 11.732851985559567, ROIC , revenue growth 1y , 6m momentum 
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05
Base cash flow: -346813000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ELVN (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 53
Market cap: 3782657024 (USD: 3782657024)
P/B ratio: 6.176878620978682
Debt to equity: 0.0007000000000000001
Current ratio: 40.32
Return on net tangible assets (%): -5.20838617890662
Buffett classification: The Gruesome
Analyst consensus upside (%): 70.6377551020408
Rule of 40 score: 0
Altman Z-score: 197.43105084527824 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.002564335052968313
Total shareholder yield (%): 0.002564335052968313 (Low Return)
Momentum (%): 1m 10.948293908310648, 3m 19.774011299435028, 6m 105.58572536850271, 12m 141.45785876993168, composite 80.99690538893294 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 7, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: -0.009215532082208667
FCF conversion rate: 0.8164811444533796
Beneish M-score: -2.0596746079487525 (Likely Safe)
ROE (%): -5.175882974703302
Asset turnover: 0
Equity multiplier (leverage): 1.0307295460395525
ROE archetype: Low Return
Treasury beta 1y: 0.0006045982496896127 (R-squared: 1.0724213535133266e-05)
Insider 90-day net shares: -1188567 (net value USD: -53795006.00)
Incremental ROIC 3y (%): -42.75641832200032 (pretax: -54.12204850886116)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 51.08303249097473, ROIC , revenue growth 1y , 6m momentum 2.166064981949458
Sector percentiles: P/E , 6m momentum 1.7908309455587392
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.061196973099355755
Base cash flow: -103486000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for EMAN.L (Communication Services — Entertainment, United Kingdom)
Report date: 2025-12-31 (annual)
Stock price: 0.006666666666666667
Market cap: 45811408 (USD: 61907308.10810811)
P/B ratio: 0.009627496483656699
Debt to equity: 5.1174
Current ratio: 0.52
Interest coverage ratio: -0.4486787204450626
Return on net tangible assets (%): -44.86892224960789
Buffett classification: The Gruesome
Rule of 40 score: 18.928122256361082
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 4.3342377568175845
Total shareholder yield (%): 4.3342377568175845 (Moderate Return)
Momentum (%): 1m 10.14492753623189, 3m 45.098039215686256, 6m 76.19047619047619, 12m 20.325203252032534, composite 43.51037804937979 (Flat)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 9, recommendation: Short
Revenue growth 1y (%): 17.61332586540427
Revenue CAGR 3y (%): 18.38682532236877
Revenue deceleration: no
Revenue growth consistency score: 12.61875493288702
Beneish M-score: -2.511434134967921 (Likely Safe)
ROE (%): -34.27808452234818
Net margin (%): -8.873374729836359
Asset turnover: 0.6177698234387978
Equity multiplier (leverage): 6.253181474063656
ROE archetype: Low Return
FCF z-score: 4.394300589052169
Treasury beta 1y: 0.00027614054843383965 (R-squared: 6.680409303170378e-06)
Insider 90-day net shares: 2042177 (net value USD: 983732.00)
ROIC (%): -1.6485587870006213 (pretax: -2.0867832746843304)
Incremental ROIC 3y (%): -14.208902473970781 (pretax: -17.98595249869719)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 0.9433962264150944, ROIC 49.056603773584904, revenue growth 1y 16.9811320754717, 6m momentum 1.4150943396226416
Sector percentiles: P/E , 6m momentum 2.115541090317331
Industry median P/E: 3.7313797891504157; industry median ROIC: 1.542068936425999
Sector median P/E: 1.436628982900151; sector median ROIC: 4.830798676039866
WACC: 0.05
Base cash flow: -10824324.324324325
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for EMH.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2026-03-31 (quarterly)
Stock price: 0.15972222222222224
Market cap: 55828644 (USD: 38238797.26027397)
Debt to equity: 0.0264
Current ratio: 0.19
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -17.28670634920635, 3m -25.46296296296296, 6m -40.206552706552706, 12m 41.87091503267975, composite 1.950594168308849 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 4, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.0016585125997477753 (R-squared: 4.5485426594074616e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -8.553707941467724 (pretax: -10.827478406921172)
Incremental ROIC 3y (%): 7.671828526290264 (pretax: 9.71117534973451)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC 21.981681931723564, revenue growth 1y , 6m momentum 53.62198168193172
Sector percentiles: P/E , 6m momentum 63.85341476957246
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.06468577497155316
Base cash flow: -5512212.080536912
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ETSY (Consumer Cyclical — Internet Retail, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 80.62
Market cap: 7650534400 (USD: 7650534400)
P/E ratio: 19.149425287356323
Debt to equity: -2.705469920976152
Current ratio: 1.69
Return on net tangible assets (%): -7.031676265535011
Buffett classification: The Great
Analyst consensus upside (%): 52.721088435374156
Rule of 40 score: -25.55887834837326
Altman Z-score: 0.6758198648719749 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 11.256506637662701, earnings yield % 1.2885915038170401, rank 586
Dividend yield (%): 0
Buyback yield (%): 1.8982072677171415
Debt paydown yield (%): -0.0006927620637847208
Total shareholder yield (%): 1.8975145056533569 (Low Return)
Momentum (%): 1m 3.33247885157653, 3m 28.39624143971971, 6m 33.987036729267075, 12m 26.00812753985622, composite 28.109211926913485 (Moderate Uptrend)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 4, short score 10, recommendation: Neutral
Revenue growth 1y (%): 3.115464779713961
Revenue deceleration: no
Accrual ratio: -0.00043570556252583596
FCF conversion rate: 1.0172215843857635
Beneish M-score: -2.376879072239641 (Likely Safe)
Net margin (%): 11.03794372359519
Asset turnover: 0.22920908366218512
ROE archetype: Standard Business
P/E z-score: 4.08025804602423
FCF z-score: 4.850609362622764
Treasury beta 1y: -0.00617183020252439 (R-squared: 0.0023869156405633635)
Insider 90-day net shares: -813888 (net value USD: -57748177.00)
ROIC (%): 67.96058234973592 (pretax: 102.85489836483544)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 36.423841059602644, P/B , ROIC 3.3112582781456954, revenue growth 1y 35.099337748344375, 6m momentum 3.3112582781456954
Sector percentiles: P/E 53.30319888734353, 6m momentum 7.579972183588317
Industry median P/E: 2.072622107969152; industry median ROIC: 4.884758827297602
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.0949277750539821
Base cash flow: 249441000
DCF price per share: base 27.59450607922377, conservative 20.394761955091234, aggressive 36.68624126981343
Financial scorecard for EUREKAFORB.NS (Consumer Cyclical — Furnishings, Fixtures & Appliances, India)
Report date: 2026-03-31 (annual)
Stock price: 4.460672997522709
Market cap: 83623968768 (USD: 886222644.8495125)
P/E ratio: 0.5570770224925778
P/B ratio: 1.8440486485581884
Debt to equity: 0.0063
Current ratio: 1.07
Interest coverage ratio: 31.130834439791645
Return on net tangible assets (%): -25.53703176680481
Buffett classification: The Good
Analyst consensus upside (%): 13973.328715794256
Rule of 40 score: 5.950103242445413
Altman Z-score: 2.497677736263275 (Grey Zone)
Piotroski F-score: 2 (Weak)
Magic formula: return on capital % 15.264048410719559, earnings yield % 0.008710626626860252, rank 1686
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.008711466442471047
Total shareholder yield (%): -0.008711466442471047 (Minimal or Negative)
Momentum (%): 1m -8.191835678622246, 3m -17.695532634670702, 6m -21.9382225433526, 12m -31.550990678276868, composite -21.692398318404884 (Strong Downtrend)
Lynch category: Slow Grower (confidence: Low)
Screener: long score 9, short score 3, recommendation: Long
Revenue growth 1y (%): 1.1680939227390663
Net income growth 1y (%): -6.528823901850334
Revenue deceleration: no
Accrual ratio: 5.4741207347642775e-05
FCF conversion rate: 0.9976898836333451
Beneish M-score: -2.3768993214290663 (Likely Safe)
ROE (%): 1.1093555049809214
Net margin (%): 7.4642746821490995
Asset turnover: 0.10151555420013442
Equity multiplier (leverage): 1.4640319010598661
ROE archetype: Low Return
P/E z-score: 3.027846980324157
FCF z-score: 3.027846980324158
Treasury beta 1y: 0.0009492046762516345 (R-squared: 0.00016520944496281208)
Insider 90-day net shares: -22576 (net value USD: -164166.00)
ROIC (%): 4.354214893091311 (pretax: 5.871721451060834)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 32.515337423312886, P/B 52.760736196319016, ROIC 48.466257668711656, revenue growth 1y 24.539877300613497, 6m momentum 71.16564417177914
Sector percentiles: P/E 32.127955493741304, 6m momentum 67.73296244784423
Industry median P/E: 0.5336405520626155; industry median ROIC: 5.666341450255377
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.05
Base cash flow: 15348378.550233152
DCF price per share: base 0.04342691458743374, conservative 0.0319600799747004, aggressive 0.061926016959589984